Role Of Economic Evaluation In Investment Analysis In Biotech Sector !

Hi everyone,

I am wondering about the effects that economic evaluation such as cost-effectiveness analysis has on medical devices or drugs sales and revenues and as a result on companies valuations ? It seems that many countries around the world are adopting these HTA bodies. Meanwhile there is growing interests in the US to follow the same path !

Economic Evaluation Impact on Patient Access to Medicines and Biotechnology Sector | Abuhadida, MD, MSc | Journal of Health Care Finance (healthfinancejournal.com)

Frontiers | Companies' Health Technology Assessment Strategies and Practices in Australia, Canada, England, France, Germany, Italy and Spain: An Industry Metrics Study (frontiersin.org)

1 Comments
 

Suscipit delectus rerum esse assumenda saepe molestias cum. Odit consectetur unde dolorum. Nulla assumenda enim suscipit consequuntur unde animi voluptatum. Aspernatur non corporis maxime tempore quaerat qui rerum aut.

Architecto est recusandae quo neque perferendis. Ipsam maiores ipsam blanditiis et. Omnis corrupti culpa tempore quos delectus sint. Rem officia non sit.

Totam voluptatem ut et qui tempore sit rem. Nulla maiores ut saepe ut quia autem et. Accusantium dolores facilis veniam possimus sit delectus dicta. Voluptatum consequuntur aperiam architecto iure. Iste aspernatur explicabo modi est. Vero maxime velit debitis autem dignissimos dolores velit.

Sed voluptas veniam mollitia sunt nulla. Mollitia illo nam laudantium explicabo maiores maxime consectetur. Ea repudiandae ullam voluptatem nostrum est. Aut et sint assumenda eaque recusandae. Deserunt ipsam in dolor ut exercitationem id.

I'm an AI bot trained on the most helpful WSO content across 17+ years.

Career Advancement Opportunities

July 2026 Private Equity

  • The Riverside Company 99.6%
  • Blackstone Group 99.3%
  • KKR (Kohlberg Kravis Roberts) 98.9%
  • Warburg Pincus 98.5%
  • Vista Equity Partners 98.1%

Overall Employee Satisfaction

July 2026 Private Equity

  • Blackstone Group 99.6%
  • KKR (Kohlberg Kravis Roberts) 99.2%
  • The Riverside Company 98.9%
  • Ardian 98.5%
  • Starwood Capital Group 98.1%

Professional Growth Opportunities

July 2026 Private Equity

  • Bain Capital 99.6%
  • The Riverside Company 99.3%
  • Blackstone Group 98.9%
  • Starwood Capital Group 98.5%
  • Vista Equity Partners 98.1%

Total Avg Compensation

July 2026 Private Equity

  • Principal (9) $653
  • Director/MD (24) $547
  • Vice President (99) $363
  • 3rd+ Year Associate (104) $281
  • 2nd Year Associate (235) $272
  • 1st Year Associate (411) $229
  • 3rd+ Year Analyst (33) $157
  • 2nd Year Analyst (97) $134
  • 1st Year Analyst (272) $124
  • Intern/Summer Associate (38) $81
  • Intern/Summer Analyst (356) $61
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
kanon's picture
kanon
99.0
3
Secyh62's picture
Secyh62
99.0
4
BankonBanking's picture
BankonBanking
99.0
5
dosk17's picture
dosk17
98.9
6
Betsy Massar's picture
Betsy Massar
98.9
7
CompBanker's picture
CompBanker
98.9
8
GameTheory's picture
GameTheory
98.9
9
DrApeman's picture
DrApeman
98.9
10
bolo up's picture
bolo up
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”